Capital Markets Day: Commercial Execution and Innovation in Obesity Care
12
Commercial execution and innovation
Obesity care
There remains a large opportunity for activating more people
with obesity to seek treatment
WegovyⓇ patient characteristics in the US
Despite the early success of WegovyⓇ,
activating patients remains the focus
ONCE-WEEKLY
wegovy
semaglutide injection 2.4 mg
75%
.
81% Female
Average BMI 38.8
of patients new to anti-
obesity medication1
•
38% have ≥3 co-morbidities
Of the people with overweight or obesity in the US,
almost 90% have a weight-related comorbidity
YOU'RE READY
for
THE TRUTH
BMI
27-30 30-35 35-40
≥40
140
Total
(million of people)
(43)
(52)
(25)
(20)
it's
million people with a
BMI > 27
No obesity-related comorbidity²
Any obesity-related comorbidity
7
6
2
2
17
BIGGER
36
46
23
18
123
than ME
Hereof metabolic syndrome³
21
26
14
12
72
1 Patients new to anti-obesity medication reflect source of business, where 75% of patients starting WegovyⓇ are naïve to anti-obesity medication treatment and 25% have either switched from or restarted anti-obesity treatment, IQVIA Feb. 2022;
2 Individuals without any of the following obesity related conditions: T2DM, Pre-diabetes, NASH, NAFLD, obstructive sleep apnea, osteoarthritis, PCOS, ASCVD, Heart failure, asthma, urinary incontinence, hypertension, chronic kidney disease stg. 3 or 4,
musculoskeletal pain, dyslipideamia, metabolic syndrome; 3 Metabolic syndrome defined as two or more of dyslipidaemia; hypertension; prediabetes OR type II diabetes
Source: Novo Nordisk real world research; National Health And Examination Survey (NHANES) cycles 2015-2016 and 2017-2018
Novo NordiskⓇ
CMD22
CAPITAL MARKETS DAYView entire presentation